by Sébastien Guibert | 15 Jan 2019 | General news, Research
IMLINFO is a cross-border network of personalized immunotherapies for Non-Hodgkin’s lymphomas (NHL) involving 7 organizations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments through the creation of a...
by Sébastien Guibert | 3 Apr 2018 | General news, Research
Discover in this France 3 TV report the collaboration between the CRCT team led by Dr. Pierre Cordelier and the Toulouse start-up Neovirtech: a therapeutic innovation opening up new perspectives in the treatment of cancer....
by Sébastien Guibert | 22 Mar 2018 | General news, Research
Thanks to anticancer immunotherapies targeting immune checkpoints, the proportion of patients with metastatic melanoma (MM) in remission after 5 years has tripled during the last years. However, therapeutic options are sparse for patients who do not respond to...
by Sébastien Guibert | 29 Nov 2017 | General news
Pr. Hervé Avet-Loiseau, Director of CRCT’s team 13 “Pharmacogenomics of multiple myeloma” and Director of IUCT-O’s Unit “Genomics of Myeloma” is laureate of the 2017 Prize Rosen from the Fondation pour la Recherche Médicale (FRM)...
by Sébastien Guibert | 28 Nov 2017 | General news
Better target the tumor and its immune environment to defeat multiple myeloma The ARC Foundation awarded a grant of 400,000 euros to Professor Hervé Avet-Loiseau for his work on multiple myeloma, the second most common malignant hemopathy (blood cancer), with more...
by cosi | 28 Jun 2017 | General news
Julie Guillermet-Guibert, Director of CRCT’s team 17, has been awarded with the first “Prize Forcheurs Jean-Marie Lehn”. This distinction, received from the Nobel Prize Jean-Marie Lehn, awards the collaboration developped between Dr. Julie...
